Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

ClinicalTrials.gov ID: NCT05412979

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05412979. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Crossover, Phase 2 Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

ST-1891-201 is a multicenter, randomized, double-blind, partial crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary hypothyroidism.

Study identification

NCT ID
NCT05412979
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sention Therapeutics, LLC
Industry
Enrollment
490 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2022 (Actual)
Primary completion
Oct 4, 2023 (Actual)
Completion
Oct 4, 2023 (Actual)
Last update posted
Aug 26, 2024

2022 – 2023

United States locations

U.S. sites
39
U.S. states
17
U.S. cities
38
Facility City State ZIP Site status
Sention Investigational Site Greenbrae California 94904 —
Sention Investigational Site Newhall California 91321 —
Sention Investigational Site Denver Colorado 80246 —
Sention Investigational Site Fort Lauderdale Florida 33312 —
Sention Investigational Site Jacksonville Florida 32258 —
Sention Investigational Site New Port Richey Florida 34652 —
Sention Investigational Site Palm Harbor Florida 34684 —
Sention Investigational Site Atlanta Georgia 30318 —
Sention Investigational Site Lawrenceville Georgia 30046 —
Sention Investigational Site Roswell Georgia 30076 —
Sention Investigational Site Evergreen Park Illinois 60805 —
Sention Investigational Site Newburgh Indiana 47630 —
Sention Investigational Site South Bend Indiana 46617 —
Sention Investigational Site Ankeny Iowa 50023 —
Sention Investigational Site Louisville Kentucky 40213 —
Sention Investigational Site Dearborn Michigan 48126 —
Sention Investigational Site Chesterfield Missouri 63017 —
Sention Investigational Site Jefferson City Missouri 65109 —
Sention Investigational Site Staten Island New York 10301 —
Sention Investigational Site Cary North Carolina 27518 —
Sention Investigational Site Greenville North Carolina 27834 —
Sention Investigational Site Hickory North Carolina 28601 —
Sention Investigational Site Morehead City North Carolina 28557 —
Sention Investigational Site Raleigh North Carolina 27609 —
Sention Investigational Site Rocky Mount North Carolina 27804 —
Sention Investigational Site Salisbury North Carolina 28144 —
Sention Investigational Site Wilmington North Carolina 28401 —
Sention Investigational Site Mt. Pleasant South Carolina 29464 —
Sention Investigational Site Bristol Tennessee 37620 —
Sention Investigational Site Chattanooga Tennessee 37411 —
Sention Investigational Site Memphis Tennessee 38133 —
Sention Investigational Site Austin Texas 78731 —
Sention Investigational Site Austin Texas 78749 —
Sention Investigational Site Benbrook Texas 76132 —
Sention Investigational Site Live Oak Texas 78233 —
Sention Investigational Site Round Rock Texas 78681 —
Sention Investigational Site Webster Texas 77598 —
Sention Investigational Site Virginia Beach Virginia 23462 —
Sention Investigational Site Renton Washington 98057 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05412979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 26, 2024 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.